Ranolazine became the first approved member of a new family of antianginal medications in nearly 25 years when it was licensed in 2006 for the treatment of chronic angina pectoris. The exact mechanism of action of Ranolazine is unclear. Ranolazine was originally believed to work by partially inhibiting the oxidation of fatty acids. Ranolazine may lessen calcium excess in ischemic myocytes by inhibiting the late sodium current, according to more recent data. Headache, nausea, constipation, and dizziness are the most commonly reported side effects. Ranolazine is listed among the top 200 drugs by sales in the decade of the 2010s. In this study, several impurities related to Ranolazine, a piperazine derivative used as a second-line treatment for patients with stable or poorly managed chronic angina who are not responding to other medications, the synthesis of impurities produced during the bulk drug's in-house production of Ranolazine was explained. The unknown impurities were identified as2,2'-(4,4'-(oxybis(2-hydroxypropane-3,1-diyl))bis(piperazine-4,1- diyl))bis(N-(2,6-dimethylphenyl)acetamide). The study uses a variety of spectral techniques, such as Infrared Spectroscopy (IR): A technique for determining molecular vibrations and functional groups. Atomic connectivity and structure can be thoroughly understood through nuclear magnetic resonance (NMR). The molecular weight and fragmentation patterns of compounds are ascertained through mass spectrometry (mass). Utilizing High-Performance Liquid Chromatography (HPLC), various compounds in a mixture can be separated and examined.
| Published in | American Journal of Applied Scientific Research (Volume 11, Issue 2) |
| DOI | 10.11648/j.ajasr.20251102.12 |
| Page(s) | 120-126 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2025. Published by Science Publishing Group |
Ranolazine, Impurities, Bulk Drug, Synthesis, Contaminants
| [1] | Abburu, S. R., Alapati, M. L. P. R., Dadhich, A. S., & Rao, M. K. (2016). Determination of ranolazine in tablet formulations by high-performance thin-layer chromatography—mass spectrometry using reflectance scanning densitometry. JPC–Journal of Planar Chromatography–Modern TLC, 29, 190-194. |
| [2] | Peate, I. (2022). Angina–management of chest pain. British Journal of Healthcare Assistants, 16(3), 110-115. |
| [3] | Martínez López, I., Gómez Cerezo, J. F., Gámez, J. M., Egocheaga Cabello, I., Castellanos, M., Campuzano Ruiz, R.,... & Mostaza, J. M. (2024). Post-event follow-up costs in patients with atherosclerotic cardiovascular disease in Spain. Frontiers in cardiovascular medicine, 11, 1324537. |
| [4] | Tadrous, M., Shakeri, A., Hayes, K. N., Neville, H. L., Houlihan, J., Clement, F.,... & Gomes, T. (2021). Canadian trends and projections in prescription drug purchases: 2001–2023. Canadian Journal of Health Technologies, 1(11). |
| [5] | Rashid, A., Movio, G., & Lee, G. C. (2022). Nicorandil and ranolazine overdose management. BMJ Case Reports CP, 15(12), e245834. |
| [6] | Asendrych-Wicik, K., Zarczuk, J., Walaszek, K., Ciach, T., & Markowicz-Piasecka, M. (2023). Trends in development and quality assessment of pharmaceutical formulations-F2α analogues in the glaucoma treatment. European Journal of Pharmaceutical Sciences, 180, 106315. |
| [7] | Singh A, Afreen S & Dhirendra P, World J Pharm Pharm Sci, 6647 (2017) 1337. |
| [8] | Roy J, AAPs Pharm Sci Tech, 3 (2002) 1. |
| [9] | Pilaniya K, Chandrawanshi H K, Pilaniya U, Manchandani P, Jain P & Singh N, J Adv Pharm Tech, 1 (2010) 302. |
| [10] | Hoyt, E. M., Smith, L. O., & Crittenden, D. L. (2023). Simple, accurate, adjustable-parameter-free prediction of NMR shifts for molecules in solution. Physical Chemistry Chemical Physics, 25(14), 9952-9957. |
| [11] | Venkateswara Rao, G., Pindi, S. R., Hari Babu, B., & Khandapu, B. M. K. (2024). Synthesis of potential impurities of cloxacillin sodium drug substance. Journal of Heterocyclic Chemistry, 61(2), 341-346. |
APA Style
Mali, N. L., Mehta, R., Mehta, P., Sen, P. (2025). Synthesis and Characterization of Ether-Dimer Impurity of Drug - Ranolazine Using 2, 2’- (oxybis (methylene)) Bis (Oxirane). American Journal of Applied Scientific Research, 11(2), 120-126. https://doi.org/10.11648/j.ajasr.20251102.12
ACS Style
Mali, N. L.; Mehta, R.; Mehta, P.; Sen, P. Synthesis and Characterization of Ether-Dimer Impurity of Drug - Ranolazine Using 2, 2’- (oxybis (methylene)) Bis (Oxirane). Am. J. Appl. Sci. Res. 2025, 11(2), 120-126. doi: 10.11648/j.ajasr.20251102.12
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ajasr.20251102.12,
author = {Nand Lal Mali and Rajeev Mehta and Preeti Mehta and Pankaj Sen},
title = {Synthesis and Characterization of Ether-Dimer Impurity of Drug - Ranolazine Using 2, 2’- (oxybis (methylene)) Bis (Oxirane)
},
journal = {American Journal of Applied Scientific Research},
volume = {11},
number = {2},
pages = {120-126},
doi = {10.11648/j.ajasr.20251102.12},
url = {https://doi.org/10.11648/j.ajasr.20251102.12},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajasr.20251102.12},
abstract = {Ranolazine became the first approved member of a new family of antianginal medications in nearly 25 years when it was licensed in 2006 for the treatment of chronic angina pectoris. The exact mechanism of action of Ranolazine is unclear. Ranolazine was originally believed to work by partially inhibiting the oxidation of fatty acids. Ranolazine may lessen calcium excess in ischemic myocytes by inhibiting the late sodium current, according to more recent data. Headache, nausea, constipation, and dizziness are the most commonly reported side effects. Ranolazine is listed among the top 200 drugs by sales in the decade of the 2010s. In this study, several impurities related to Ranolazine, a piperazine derivative used as a second-line treatment for patients with stable or poorly managed chronic angina who are not responding to other medications, the synthesis of impurities produced during the bulk drug's in-house production of Ranolazine was explained. The unknown impurities were identified as2,2'-(4,4'-(oxybis(2-hydroxypropane-3,1-diyl))bis(piperazine-4,1- diyl))bis(N-(2,6-dimethylphenyl)acetamide). The study uses a variety of spectral techniques, such as Infrared Spectroscopy (IR): A technique for determining molecular vibrations and functional groups. Atomic connectivity and structure can be thoroughly understood through nuclear magnetic resonance (NMR). The molecular weight and fragmentation patterns of compounds are ascertained through mass spectrometry (mass). Utilizing High-Performance Liquid Chromatography (HPLC), various compounds in a mixture can be separated and examined.
},
year = {2025}
}
TY - JOUR T1 - Synthesis and Characterization of Ether-Dimer Impurity of Drug - Ranolazine Using 2, 2’- (oxybis (methylene)) Bis (Oxirane) AU - Nand Lal Mali AU - Rajeev Mehta AU - Preeti Mehta AU - Pankaj Sen Y1 - 2025/04/29 PY - 2025 N1 - https://doi.org/10.11648/j.ajasr.20251102.12 DO - 10.11648/j.ajasr.20251102.12 T2 - American Journal of Applied Scientific Research JF - American Journal of Applied Scientific Research JO - American Journal of Applied Scientific Research SP - 120 EP - 126 PB - Science Publishing Group SN - 2471-9730 UR - https://doi.org/10.11648/j.ajasr.20251102.12 AB - Ranolazine became the first approved member of a new family of antianginal medications in nearly 25 years when it was licensed in 2006 for the treatment of chronic angina pectoris. The exact mechanism of action of Ranolazine is unclear. Ranolazine was originally believed to work by partially inhibiting the oxidation of fatty acids. Ranolazine may lessen calcium excess in ischemic myocytes by inhibiting the late sodium current, according to more recent data. Headache, nausea, constipation, and dizziness are the most commonly reported side effects. Ranolazine is listed among the top 200 drugs by sales in the decade of the 2010s. In this study, several impurities related to Ranolazine, a piperazine derivative used as a second-line treatment for patients with stable or poorly managed chronic angina who are not responding to other medications, the synthesis of impurities produced during the bulk drug's in-house production of Ranolazine was explained. The unknown impurities were identified as2,2'-(4,4'-(oxybis(2-hydroxypropane-3,1-diyl))bis(piperazine-4,1- diyl))bis(N-(2,6-dimethylphenyl)acetamide). The study uses a variety of spectral techniques, such as Infrared Spectroscopy (IR): A technique for determining molecular vibrations and functional groups. Atomic connectivity and structure can be thoroughly understood through nuclear magnetic resonance (NMR). The molecular weight and fragmentation patterns of compounds are ascertained through mass spectrometry (mass). Utilizing High-Performance Liquid Chromatography (HPLC), various compounds in a mixture can be separated and examined. VL - 11 IS - 2 ER -
Department of Chemistry, Sangam University, Bhilwara, India
Department of Chemistry, Sangam University, Bhilwara, India
Department of Chemistry, Sangam University, Bhilwara, India
Department of Chemistry, Sangam University, Bhilwara, India
